Merck & Co., one of the world’s top developers and sellers of vaccines, has entered a partnership with a small drug developer to research and manufacture a potential Ebola vaccine now in initial patient testing. The exclusive deal involves a vaccine candidate called rVSV-EBOV that’s under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of Ames, Iowa .
Are you up for a challenge?
